Kidney News and Research

RSS
New research could help develop precision medicine for primary aldosteronism

New research could help develop precision medicine for primary aldosteronism

Only 1 in 4 patients with ESRD in Georgia referred for kidney transplant evaluation

Only 1 in 4 patients with ESRD in Georgia referred for kidney transplant evaluation

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Southern-style diet may increase risk of heart disease

Southern-style diet may increase risk of heart disease

Researchers develop new technology to track DNA-protein binding in live cells

Researchers develop new technology to track DNA-protein binding in live cells

LA BioMed researcher launches study to examine medication adherence among patients with dialysis

LA BioMed researcher launches study to examine medication adherence among patients with dialysis

Lund University researchers discovered 'main switch' that regulates cell invaginations

Lund University researchers discovered 'main switch' that regulates cell invaginations

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

Findings by Joslin scientists may lead to early detection, treatment of complications in type 1 diabetes

Findings by Joslin scientists may lead to early detection, treatment of complications in type 1 diabetes

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Scientists develop artificial blood vessels that are resistant to blood clot formation

Scientists develop artificial blood vessels that are resistant to blood clot formation

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Integrated treatment required for diabetes-eating disorder combination

Integrated treatment required for diabetes-eating disorder combination

IDIBELL licenses a tool to Oxford Immunotec to improve efficiency of kidney transplants, prevent graft rejection

IDIBELL licenses a tool to Oxford Immunotec to improve efficiency of kidney transplants, prevent graft rejection

UChicago Medicine contributes to Illinois Transplant Fund

UChicago Medicine contributes to Illinois Transplant Fund

Surgeons describe positive outcomes in kidney cancer patients treated with robotic IVC thrombectomy

Surgeons describe positive outcomes in kidney cancer patients treated with robotic IVC thrombectomy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.